Xencor, Inc Additional Paid in Capital
Xencor, Inc (XNCR) had Additional Paid in Capital of $1.45 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapital · last filed 2026-08-05
- 2026-06-30: Additional Paid in Capital $1.45B.
- 2026-03-31: Additional Paid in Capital $1.44B.
- 2025-12-31: Additional Paid in Capital $1.43B.
- 2025-09-30: Additional Paid in Capital $1.41B.
| Period end | Additional Paid in Capital |
|---|---|
| 2026-06-30 | $1.45B 10-Q · filed 2026-08-05 |
| 2026-03-31 | $1.44B 10-Q · filed 2026-05-06 |
| 2025-12-31 | $1.43B 10-Q · filed 2026-08-05 |
| 2025-09-30 | $1.41B 10-Q · filed 2025-11-05 |
| 2025-06-30 | $1.40B 10-Q · filed 2025-08-06 |
| 2025-03-31 | $1.39B 10-Q · filed 2025-05-07 |
| 2024-12-31 | $1.38B 10-K · filed 2026-02-25 |
| 2024-09-30 | $1.36B 10-Q/A · filed 2025-02-24 |
| 2024-06-30 | $1.16B 10-Q/A · filed 2025-02-24 |
| 2024-03-31 | $1.14B 10-Q/A · filed 2025-02-24 |
| 2023-12-31 | $1.13B 10-K · filed 2025-02-27 |
| 2023-09-30 | $1.11B 10-Q · filed 2023-11-08 |
| 2023-06-30 | $1.10B 10-Q · filed 2023-08-03 |
| 2023-03-31 | $1.09B 10-Q · filed 2023-05-08 |
| 2022-12-31 | $1.07B 10-K/A · filed 2025-02-24 |
| 2022-09-30 | $1.06B 10-Q · filed 2022-11-07 |
| 2022-06-30 | $1.04B 10-Q · filed 2022-08-03 |
| 2022-03-31 | $1.03B 10-Q · filed 2022-05-05 |
| 2021-12-31 | $1.02B 10-K · filed 2023-02-27 |
| 2021-09-30 | $974.51M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $962.34M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $951.15M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $937.52M 10-K · filed 2022-02-24 |
| 2020-09-30 | $919.39M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $908.08M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $895.86M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $887.87M 10-K · filed 2021-02-24 |
| 2019-09-30 | $877.72M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $865.16M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $851.89M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $845.37M 10-K · filed 2020-02-25 |
| 2018-09-30 | $839.13M 10-Q · filed 2018-11-05 |
| 2018-06-30 | $828.86M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $821.67M 10-Q · filed 2018-05-07 |
| 2017-12-31 | $570.67M 10-K · filed 2019-02-26 |
| 2017-09-30 | $566.61M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $562.02M 10-Q · filed 2017-08-07 |
| 2017-03-31 | $557.47M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $552.89M 10-K · filed 2018-02-28 |
| 2016-09-30 | $431.15M 10-Q · filed 2016-11-02 |
| 2016-06-30 | $428.79M 10-Q · filed 2016-08-03 |
| 2016-03-31 | $426.29M 10-Q · filed 2016-05-02 |
| 2015-12-31 | $424.13M 10-K · filed 2017-03-01 |
| 2015-09-30 | $422.26M 10-Q · filed 2015-11-04 |
| 2015-06-30 | $421.06M 10-Q · filed 2015-08-05 |
| 2015-03-31 | $419.37M 10-Q · filed 2015-05-05 |
| 2014-12-31 | $302.97M 10-K · filed 2016-03-08 |
| 2014-09-30 | $302.04M 10-Q · filed 2014-11-10 |
| 2014-06-30 | $301.57M 10-Q · filed 2014-08-01 |
| 2014-03-31 | $301.07M 10-Q · filed 2014-05-15 |
| 2013-12-31 | $300.79M 10-K · filed 2015-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |